KMTS Healthcare

Kestra Medical Technologies, Ltd.

$29.01-2.68%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States
Market cap: 1.7B USD
Enterprise value: 1.5B USD
Full-time employees: 443

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Kestra Medical Technologies looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 92% of peers, at an operating loss.
Revenue grew faster than 92% of peers, but the business runs at an operating loss (margin -134%).

StockQuotient Score

46/ 100

Oct 5 46 → Nov 4 46

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-8.7%

SEC filings · 12 months to Jul 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-8.4%

SEC filings · 12 months to Jul 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-7.1%

SEC filings · 12 months to Jul 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield12.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

93/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 12.2%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth131.9%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Apr 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth60.7%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score 5.61Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

14/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ Operating margin
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-134.5%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -11.63Sector median: 0.0706 · MAD: 0.1217

Return on assets-43.1%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -8.35Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-50.1%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -5.46Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin53.9%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-67.4%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: Changed: worth a look

Debt up 70%

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio4.69×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.52Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.33×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.51Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Kestra Medical Technologies

Is Kestra Medical Technologies getting weaker?: Its latest SEC filing (Sep 14, 2026) showed no major changes: debt up 70%. Its overall score is unchanged at 46/100 since Oct 28, 2026.
How is Kestra Medical Technologies valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.7% vs peers 1.5% (weaker than 100% of peers).
Is Kestra Medical Technologies growing?: Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 131.9% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 131.9% vs peers 5.8% (stronger than 95% of peers).
How profitable is Kestra Medical Technologies?: Less profitable than most of its peers. Profitability scores 14/100 against 1,393 healthcare peers. Return on assets -43.1% vs a peer median of 1.7% (weaker than 92% of peers).Return on assets -43.1% vs peers 1.7% (weaker than 92% of peers).
How risky is Kestra Medical Technologies?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.69× vs a peer median of 2.59× (stronger than 71% of peers).Current ratio 4.69× vs peers 2.59× (stronger than 71% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jul 31, 2026 · filed Sep 14, 2026 · compared with the quarter ended Apr 30, 2026

No major changes

Debt up 70%

Worth watching: Kestra Medical Technologies is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	95.1M USD	106.7M USD	+12.2%
Net income (12 months)	−131.6M USD	−149.9M USD	+13.9%
Operating margin	-141.6%	-134.5%	+7.2 pts
Free cash flow (12 months)	−116.6M USD	−122.8M USD	+5.3%
Debt	42.6M USD	72.5M USD	+70.0%
Cash	99.7M USD	68.6M USD	−31.2%
Shares outstanding	58.6M	59.6M	+1.6%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Instruments & Supplies · 25 companies

Valuations in Medical Instruments & Supplies are near the bottom of their range since Jul 2018.

18% of months since Jul 2018 were valued lower than now.
0% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +17% vs the whole market, against a usual +86%.

Jul 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Apr 2024	FY Apr 2025	FY Apr 2026	Change
Gross margin	1.3%	40.5%	51.4%	▲ 11 pts
Operating margin	-305.8%	-177.8%	-141.6%	▲ 36 pts
Net margin	-338.4%	-190.3%	-138.4%	▲ 52 pts
Return on assets (ROA)	-204.8%	-38.5%	-36.7%	▲ 1.8 pts
Return on equity (ROE)	—	-55.4%	-50.7%	▲ 4.7 pts
Free cash flow margin	-303.7%	-168.1%	-122.6%	▲ 46 pts
Current ratio	0.45×	6.72×	4.41×	▼ 34%
Debt to equity	—	0.20×	0.16×	▼ 18%
Interest coverage	-13.65×	-13.75×	-17.86×	▼ 30%

KMTS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Ranks #708 of 1,157 healthcare companies (bottom 39%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Kestra Medical Technologies looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 92% of peers, at an operating loss.

Revenue grew faster than 92% of peers, but the business runs at an operating loss (margin -134%).

Questions investors ask about Kestra Medical Technologies

Is Kestra Medical Technologies getting weaker?

Its latest SEC filing (Sep 14, 2026) showed no major changes: debt up 70%. Its overall score is unchanged at 46/100 since Oct 28, 2026.

How is Kestra Medical Technologies valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.7% vs peers 1.5% (weaker than 100% of peers).

Is Kestra Medical Technologies growing?

Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers. 3-year revenue growth 131.9% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 131.9% vs peers 5.8% (stronger than 95% of peers).

How profitable is Kestra Medical Technologies?

Less profitable than most of its peers. Profitability scores 14/100 against 1,393 healthcare peers. Return on assets -43.1% vs a peer median of 1.7% (weaker than 92% of peers).Return on assets -43.1% vs peers 1.7% (weaker than 92% of peers).

How risky is Kestra Medical Technologies?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.69× vs a peer median of 2.59× (stronger than 71% of peers).Current ratio 4.69× vs peers 2.59× (stronger than 71% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

95.1M USD

106.7M USD

+12.2%

Net income (12 months)

−131.6M USD

−149.9M USD

+13.9%

Operating margin

-141.6%

-134.5%

+7.2 pts

Free cash flow (12 months)

−116.6M USD

−122.8M USD

+5.3%

Debt

42.6M USD

72.5M USD

+70.0%

Cash

99.7M USD

68.6M USD

−31.2%

Shares outstanding

58.6M

59.6M

+1.6%

Key ratios

FY Apr 2024

FY Apr 2025

FY Apr 2026

Change

Gross margin

1.3%

40.5%

51.4%

▲ 11 pts

Operating margin

-305.8%

-177.8%

-141.6%

▲ 36 pts

Net margin

-338.4%

-190.3%

-138.4%

▲ 52 pts

Return on assets (ROA)

-204.8%

-38.5%

-36.7%

▲ 1.8 pts

Return on equity (ROE)

—

-55.4%

-50.7%

▲ 4.7 pts

Free cash flow margin

-303.7%

-168.1%

-122.6%

▲ 46 pts

Current ratio

0.45×

6.72×

4.41×

▼ 34%

Debt to equity

—

0.20×

0.16×

▼ 18%

Interest coverage

-13.65×

-13.75×

-17.86×

▼ 30%